ArmstrongAW, ReadC. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA, 2020; 323(19):1945–1960. doi: 10.1001/jama.2020.4006
2.
Munera-CamposM, BallescaF, RicharzN, et al.Paradoxical eczematous reaction to ixekizumab. J Eur Acad Dermatol Venereol, 2019; 33(1):e40–e42. doi: 10.1111/jdv.15156
3.
Le Floc'hA, AllinneJ, NagashimaK, et al.Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy, 2020; 75(5):1188–1204. doi: 10.1111/all.14151
4.
Al-JanabiA, FoulkesAC, GriffithsCEM, et al.Paradoxical eczema in patients with psoriasis receiving biologics: a case series. Clin Exp Dermatol, 2022; 47(6):1174–1178. doi: 10.1111/ced.15130
5.
NapolitanoM, MegnaM, FabbrociniG, et al.Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition. Br J Dermatol, 2019; 181(3):604–606. doi: 10.1111/bjd.17779
